Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,237 signal articles · 137 in last 24h · 115,124 total before filter · latest 39m ago
137last 24h
1831last 7d
300● bullish (7d)
168● bearish (7d)
205publishers
AllMacro324Earnings882M&A104Regulatory23Product17Analyst24
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Archer Aviation stock rises as Anduril partnership unveils new autonomous VTOL defense aircraft
InvestorsHub26d agobullish
Archer Aviation stock rises as Anduril partnership unveils new autonomous VTOL defense aircraft

Archer Aviation (NYSE:ACHR) shares climbed 5% on Monday after the company introduced a new autonomous vertical takeoff and landing (VTOL) aircraft platform developed with Anduril and confirmed it will unveil its first commercial customers later this week. The companies presented the new series hybrid-electric VTOL platform at the Farnborough Airshow, highlighting its potential for both defense and commercial markets.

IREN, Hut 8 Stocks Surge as AI Deals Restore Neocloud Cheer
Barrons.com26d agobullish
IREN, Hut 8 Stocks Surge as AI Deals Restore Neocloud Cheer

IREN and Hut 8 were rising sharply early on Monday as both companies announced more customers were spending on their cloud-computing infrastructure. IREN shares rose 9% in the premarket after it said it had agreed new multiyear cloud contracts with artificial-intelligence developers representing $2.8 billion in total contract value. IREN was previously an Australian Bitcoin miner called Iris Energy before pivoting to AI computing as part of a wave of “neoclouds” building out cloud computing infrastructure.

Copper Price Rally Powers Hudbay Minerals (HBM) in Q2
Insider Monkey26d agobullish
Copper Price Rally Powers Hudbay Minerals (HBM) in Q2

L1 Capital, an investment management firm, released its “L1 Long Short Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The market’s main themes in the June quarter were the Iran conflict and developments in the AI sector. These trends shifted after oil prices declined due to a ceasefire agreement, […]

3 Not-So-Obvious AI Stocks to Buy in July
24/7 Wall St.26d agobullish
3 Not-So-Obvious AI Stocks to Buy in July

Everyone already owns NVIDIA, Microsoft, and Alphabet, but the real AI infrastructure buildout is quietly funneling billions into a different layer of the stack. Three under-the-radar names are converting that spending into hard revenue growth right now.

Investing.com26d agobullish
AMC Entertainment soars on record quarterly results

Investing.com -- AMC Entertainment Holdings, Inc. (NYSE: AMC) reported second-quarter results that exceeded analyst expectations, with the company posting its highest quarterly revenue and adjusted EBITDA in its 106-year history.

Bristol Myers buys Nvidia's latest AI computing system for drug research
Reuters26d agobullish
Bristol Myers buys Nvidia's latest AI computing system for drug research

Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia ‌to support its use of artificial intelligence across its drug discovery and development ‌operations. The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD ​based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.

Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2
Simply Wall St.26d agobullish
Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2

Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This decision broadens treatment options for a pediatric group with limited alternatives. For investors watching NasdaqGS:VRTX, the expanded approval highlights how Vertex Pharmaceuticals is building out its rare disease franchise around genetic medicines. The...